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Santa Claus is sometimes referred to as Kris Kringle, a 
name most likely derived from Christ Kindel (Christ-child). 
The German name of the Christ Child is Christkind, 
commonly used in its diminutive form Christkindel. The 
Dutch–German protestant reform movement brought in 
the idea that the Christchild should be the standard 
bearer for Christmas. Traditionally, an image used for his 
messenger was a young child with a golden crown who 
holds a tiny “Tree of Light” and brings the gifts of the 
Christ Child. We currently enjoy July, not Christmas. 
However, could it be that Kringle has brought us a 
present out of season? 
Wound repair, regeneration of ischemic tissues, and the 
new discipline of “tissue engineering” all require improved 
vascularization of the regenerating tissues. Recent 
advances in understanding the process of blood vessel 
growth have offered significant tools for therapeutic 
neovascularization [1]. Several angiogenic growth factors 
including vascular endothelial cell growth factor (VEGF) 
and basic fibroblast growth factor (bFGF) have been used 
for the vascularization of regenerating and ischemic 
tissues in animal models. Three approaches have been 
used for vascularization of bioengineered tissue: 
incorporation of angiogenic factors in the bioengineered 
tissue, seeding endothelial cells with other cell types, and 
prevascularization of matrices prior to cell seeding [1]. 
One approach is to rationally design matrices that provide 
specific adhesion molecules such as a receptor for alpha 
v beta 3-integrin expressed on angiogenic endothelial 
cells that are able to store and release angiogenic growth 
factors such as bFGF that target cell type-specific 
responses [2]. Moreover, these matrices can be modified 
to release complexed plasmid DNA or other molecules 
that transfect surrounding cells and improve 
angiogenesis. During wound healing, cells infiltrate into 
the scaffold and degrade it, thereby releasing entrapped 
growth factors. The scaffold is completely removed when 
tissue healing is achieved. 
In this issue, Zhao et al. [3] demonstrate improved 
neovascularization and wound repair by targeting human 
bFGF to fibrin. bFGF is a potent mitogen for numerous 
cell types of mesodermal origin including fibroblasts, 
vascular endothelial cells, and vascular smooth muscle 
cells and therefore holds great promise as an agent to 
promote wound healing. bFGF can be produced 
recombinantly and therefore should be readily available 
therapeutically. The problem resides in bFGF delivery. 
Exogenous bolus injection seems to work as studies 
involving the heart and ischemic limb have shown. 
However, the bFGF diffuses rapidly from the injection site 
and bFGF delivery with a sustained site-targeting result 
has been elusive. Zhao et al. [3] fused bFGF to a kringle 
repeat in the plasminogen molecule termed kringle 1 (K1). 
They thereby constructed a fusion protein (K1-bFGF) that 
has a high tendency to bind to fibrin. Plasma clots of 
course develop at the sites of wound injury. However, the 
authors also developed a fibrin-scaffold/K1-bFGF 
construct. This system successfully induced 
neovascularization by delivering K1-bFGF in a sustained 
fashion. The result was a microenvironment that promoted 
cell growth, angiogenesis, and tissue regeneration. 
What are kringle domains and whatever could they have 
to do with blood vessels? An ironical answer to this 
question comes from the molecule “angiostatin.” 
Angiostatin is a proteolytically derived internal fragment of 
plasminogen [4]. The molecule contains various members 
of the five plasminogen kringle domains that are shown in 
Fig. 1 [5]. Angiostatin is a specific angiogenesis inhibitor 
and is produced by tumors. Angiostatin inhibits primary 
and metastatic tumor growth by blocking tumor 
angiogenesis. Surprisingly, most kringle domains of 
plasminogen only inhibit angiogenesis when cleaved as 
fragments from their parent protein, which lacks 
antiangiogenic activity. These findings suggest that kringle 
domains are cryptic fragments hidden within large protein 
molecules. Thus, proteolytic processing plays a critical 
role in downregulation of angiogenesis. However, the 
antiangiogenic mechanism of angiostatin remains an 
enigma. 
Thus, we are dealing with a multipurpose molecule that on 
the one hand busts clots (plasminogen) and on the other 
inhibits the development of new blood vessels 
(angiostatin). Zhao et al. used the first kringle domain of 
this molecule to construct a fusion protein to direct bFGF 
to its target. This strategy could potentially be used in 
other clinical settings because plasminogen and 
angiostatin can promote blood vessel formation in 
ischemic cardiovascular disease and turn the process off 
in cancer, respectively. Zhao et al. [3] have picked the 
targets and vehicles to potentially do both. 
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Fig.1: Modular structure of plasminogen and contained angiostatin fragments. The full-length plasminogen amino acid sequence is 
represented as a string of letters, following the 1-letter amino acid code. Disulfide bonds are black bars connecting distant pairs of 
cysteine residues. The plasmin catalytic domain is represented in gray, kringle 5 in purple, kringle 4 in red, and kringles 1–3 in orange. 
Targeted domain within the box is kringle 1 (the figure is reproduced through the courtesy of Wahl et al. [5]) 
 
